Man Group’s Roivant Sciences ROIV Stock Holding History

Man Group’s Portfolio ROIV Stock Details ROIV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$10.3M	Sell	290,772 -561,432	-66%	-$16.6M	0.02%	779
2026 Q1	$23.6M	Sell	852,204 -604,923	-42%	-$15.5M	0.04%	433
2025 Q4	$31.6M	Buy	1,457,127 +972,973	+201%	+$19.2M	0.05%	341
2025 Q3	$7.33M	Buy	484,154 +331,642	+217%	+$4.11M	0.01%	923
2025 Q2	$1.72M	Buy	+152,512	New	+$1.65M	﹤0.01%	1461

Other funds holding ROIV

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

QVT Financial New York $1.7B AUM 173.77% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

Man Group's ROIV Position: Q2 2026 in Review

Man Group reduced its Roivant Sciences (ROIV) stake by 66% in Q2 2026, selling an estimated $16.6M and leaving 290,772 shares worth $10.3M. The position accounts for 0.02% of the portfolio, ranked #779.

Man Group first reported a position in ROIV in Q2 2025 and has held it in 5 quarters since. The position peaked at $31.6M in Q4 2025. 498 funds tracked by Wall St. Rank hold ROIV as of Q2 2026.

Man Group held 290,772 shares of Roivant Sciences worth $10.3M as of Q2 2026.
Man Group sold 561,432 Roivant Sciences shares in Q2 2026, an estimated $16.6M.
Roivant Sciences made up 0.02% of Man Group's portfolio in Q2 2026, its #779 holding.
Man Group first reported a position in Roivant Sciences in Q2 2025 and has held it in 5 quarters since.
Man Group's Roivant Sciences position peaked at $31.6M in Q4 2025.
498 funds tracked by Wall St. Rank held Roivant Sciences as of Q2 2026.

Based on Man Group's 13F filing for Q2 2026, filed 14 Aug 2026.